Abeona Therapeutics Inc.
NASDAQ:ABEO · NASDAQ Capital Market
+$0.06 today
Vol 1.07M · Avg 1.12M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
44.7%
avg -94.6%
ROIC
-44.0%
avg -58.1%
ROA
32.4%
avg -41.3%
Analysis
ROE is currently the strongest return metric at 44.7% versus its period average of -94.6%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Vishwas Seshadri | President, Chief Executive Officer & Director | $1.52M | — | 50 | $1.37M | 2.41% |
Joseph Walter Vazzano | Chief Financial Officer | $898,465.00 | — | 42 | $544,083.00 | 0.95% |
Brendan O'Malley | Chief Legal Officer | $783,926.00 | — | 57 | $440,003.00 | 0.77% |
Madhav Vasanthavada | Senior Vice President, Chief Commercial Officer & Head of Business Development | — | — | 47 | $303,229.00 | 0.53% |
Jon Voss | Vice President & Head of Quality | — | — | 66 | — | — |
James A. Gow | SVP, Head of Clinical Development & Medical Affairs | — | — | 59 | $0.00 | <0.01% |
Brian Kevany | Chief Technical & Scientific Officer | — | — | — | $0.00 | <0.01% |
Megan Callan | Vice President & Head of Quality | — | — | — | — | — |
Gregory Gin | Vice President of Investor Relations & Corporation Communications | — | — | — | — | — |
Carl Denny | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Gianine Esposito | Senior VP & Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
43
$3.77M
Net Sentiment
$3.77M
Net selling
Most Active
Vazzano Joseph Walter
9 transactions
1–10 of 43
Analysis
Insiders reported 0 buys worth $0.00 and 43 sells worth $3.77M over the last 12 months. That adds up to net selling of $3.77M. Vazzano Joseph Walter was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -38.2% | +47.4% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -38.2% over three years. Forward estimates point to Revenue at +47.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Assembly Biosciences, Inc.
NASDAQ:ASMB
$387.71M
Puma Biotechnology, Inc.
NASDAQ:PBYI
$377.67M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$243.08M
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
$228.08M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$224.16M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$217.65M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$212.60M
Humacyte, Inc.
NASDAQ:HUMA
$154.69M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$117.36M
Who manages ABEO?
Abeona Therapeutics Inc. (ABEO) lists 11 active executives. The top listed executive is Brendan O'Malley, Chief Legal Officer.
Are ABEO insiders buying or selling?
Recent insider activity shows net selling of $1.92M.
Explore More
Continue the stock analysis
Jump to another research area for this company.